摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-Nitrophenyl)-7-methyl benzimidazole | 251343-59-6

中文名称
——
中文别名
——
英文名称
2-(4-Nitrophenyl)-7-methyl benzimidazole
英文别名
4-methyl-2-(4-nitrophenyl)-1H-benzimidazole
2-(4-Nitrophenyl)-7-methyl benzimidazole化学式
CAS
251343-59-6
化学式
C14H11N3O2
mdl
——
分子量
253.26
InChiKey
OEHCBEYCJFRMCE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    19
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.07
  • 拓扑面积:
    74.5
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Benzimidazole compounds for regulating IgE
    摘要:
    本发明涉及一系列苯基苯并咪唑类似物,它们是抑制对过敏原的IgE反应的抑制剂。这些化合物在过敏和/或哮喘治疗中非常有用,或在任何IgE是致病的疾病中也可使用。
    公开号:
    US20050277686A1
  • 作为产物:
    描述:
    硼酸甘油 作用下, 以 为溶剂, 生成 2-(4-Nitrophenyl)-7-methyl benzimidazole
    参考文献:
    名称:
    硼酸和甘油的水介导合成2-取代的苯并咪唑
    摘要:
    已开发出一种非常简单,温和且高效的绿色催化剂,用于在硼酸(5摩尔%)和80℃的存在下于80°C的水中处理取代的邻苯二胺和醛来合成2-取代的苯并咪唑。甘油(0.05 mL)。该方法已在55种底物上标准化,并合成了9种新化合物。
    DOI:
    10.1071/ch08309
点击查看最新优质反应信息

文献信息

  • Benzimidazole compounds for regulating IgE
    申请人:——
    公开号:US20030100582A1
    公开(公告)日:2003-05-29
    This invention relates to a family of phenylbenzimidazole analogs, which are inhibitors of the IgE response to allergens. These compounds are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.
    这项发明涉及一类苯基苯并咪唑类似物,它们是抑制对过敏原的IgE反应的抑制剂。这些化合物在治疗过敏和/或哮喘或任何IgE致病的疾病中是有用的。
  • Remarkable Acceleration of Benzimidazole Synthesis and Cyanosilylation Reactions in a Supramolecular Solid Catalyst
    作者:Sergio Rojas-Buzo、Pilar García-García、Avelino Corma
    DOI:10.1002/cctc.201601407
    日期:2017.3.20
    A solid metal–organic catalyst with hydrophobic pockets and Lewis acid centers strongly accelerates the reaction rate for organic reactions. This is exemplified for the cyanosilylation of ketones and for the synthesis of benzimidazoles, for which very high selectivities are obtained. The solid can be recovered and reused and its behavior approaches that of a functional enzyme mimic.
    具有疏水性口袋和路易斯酸中心的固体金属有机催化剂可大大加快有机反应的反应速度。这对于酮的氰基甲硅烷化和苯并咪唑的合成是示例性的,这对于它们具有很高的选择性。固体可以回收再利用,其行为接近功能性酶模拟物的行为。
  • Benzimidazole derivatives as modulators IgE
    申请人:Avanir Pharmaceuticals
    公开号:EP1555020A2
    公开(公告)日:2005-07-20
    This invention relates to a family of diacyl benzimidazole analogs, which are inhibitors of the IgE response to allergens. These compounds are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. They have the following general structure where the substituents have the claimed values.
    本发明涉及一系列二酰苯并咪唑类似物,它们是 IgE 对过敏原反应的抑制剂。这些化合物可用于治疗过敏和/或哮喘或任何 IgE 致病的疾病。它们的一般结构如下 其中的取代基具有所要求的值。
  • Synthesis, α-glucosidase inhibitory, cytotoxicity and docking studies of 2-aryl-7-methylbenzimidazoles
    作者:Muhammad Taha、Nor Hadiani Ismail、Syahrul Imran、Muhammad Helmi Mohamad、Abdul Wadood、Fazal Rahim、Syed Muhammad Saad、Ashfaq ur Rehman、Khalid Mohammed Khan
    DOI:10.1016/j.bioorg.2016.02.004
    日期:2016.4
    Benzimidazole analogs 1-27 were synthesized, characterized by EI-MS and H-1 NMR and their alpha-glucosidase inhibitory activities were found out experimentally. Compound 25, 19, 10 and 20 have best inhibitory activities with IC50 values 5.30 +/- 0.10, 16.10 +/- 0.10, 25.36 +/- 0.14 and 29.75 +/- 0.19 respectively against alpha-glucosidase. Compound 6 and 12 has no inhibitory activity against alpha-glucosidase enzyme among the series. Further studies showed that the compounds are not showing any cytotoxicity effect. The docking studies of the compounds as well as the experimental activities of the compounds correlated well. From the molecular docking studies, it was observed that the top ranked conformation of all the compounds fit well in the active site of the homology model of alpha-glucosidase. (C) 2016 Elsevier Inc. All rights reserved.
  • BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE
    申请人:Avanir Pharmaceuticals
    公开号:EP1077700A1
    公开(公告)日:2001-02-28
查看更多